Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

News

Valvoline Says In Statement There Is ‘A Rigorous Process In Place To Determine The Optimal Path’ But No Decisions Have Been Made

-Reuters

byBenzinga Newsdesk

May 25, 2022

1 minute read

-Reuters

American Resources Selects Site In Noblesville, Indiana For New Commercial Scale Facility

By Akanksha

Today, 5:36 AM

American Resources Corp (NASDAQ:AREC) has finalized its site selection to build its first commercial-scale rare earth element purification and isolation facility…

AREC

JP Morgan Maintains Overweight on R1 RCM, Lowers Price Target to $11

By Benzinga Newsdesk

Today, 5:36 AM

JP Morgan analyst Anne Samuel maintains R1 RCM (NASDAQ:RCM) with a Overweight and lowers the price target from $33 to $11.

RCM

RBC Capital Maintains Sector Perform on Puma Biotechnology, Lowers Price Target to $6

By Benzinga Newsdesk

Today, 5:36 AM

RBC Capital analyst Kennen MacKay maintains Puma Biotechnology (NASDAQ:PBYI) with a Sector Perform and lowers the price target from $13 to $6.

PBYI

Britain To Test Merck – Ridgeback Biotherapeutics’ COVID-19 Antiviral Pill In Hospitalized Patients

By Vandana Singh

Today, 5:36 AM

British scientists will start testing Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics' COVID-19 antiviral pill molnupiravir as a possible treatment for patients hospitalized with COVID-19,

MRK

Valvoline Says In Statement There Is ‘A Rigorous Process In Place To Determine The Optimal Path’ But No Decisions Have Been Made

Related Posts

American Resources Selects Site In Noblesville, Indiana For New Commercial Scale Facility

JP Morgan Maintains Overweight on R1 RCM, Lowers Price Target to $11

RBC Capital Maintains Sector Perform on Puma Biotechnology, Lowers Price Target to $6

Britain To Test Merck – Ridgeback Biotherapeutics’ COVID-19 Antiviral Pill In Hospitalized Patients